Santhera Pharmaceuticals Marks Year of Growth with AGAMREE® Launch and Strategic Expansion
Santhera Pharmaceuticals reported a year of transformation and growth in 2024, driven by the successful launch of AGAMREE, a groundbreaking treatment for Duchenne Muscular Dystrophy, and strategic financial management.
- Santhera Pharmaceuticals Holding AG
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read